Date：23 July (Friday)
Time: 10:40 – 12:10 (GMT+8)
Didier Dargent is Head of Cell and Gene International Markets; in this role, he focuses on the commercialization of CAR-T therapies in oncology which is integrated into Novartis’ world-leading Oncology unit.
He spent 8 years in China as General Manager, including 2 years leading the Novartis Oncology team through a period of accelerated growth as one of fastest growing oncology organizations in the country. As General Manager for the Oncology business unit, he played a significant role collaborating with the Global C&G team to accelerate the launch of CAR-T in China.
Prior to joining Novartis, Didier brings with him over 15 years of pharmaceutical experience in Asia and Europe in General Management or Regional role in Asia Pacific. He held a series of sales and marketing positions in Europe at Lundbeck, Astellas, AstraZeneca.
Didier holds a Master of Business Administration from Tsinghua University, a Master of Business Administration from INSEAD, a Master of Healthcare Business Management from Ecole Supérieure de Commerce de Paris (ESCP) and a Doctor of Pharmacy from the University of Marseille in France.
Novartis is at the forefront of the science and development of immunocellular therapy as a innovative approach to treating certain cancers where there are limited options.
CAR-T cell therapy uses and modifies a patient’s own immune cells to effectively target, fight and eradicate cancer cells.
Bringing a highly innovative on-time CAR-T cell therapies to markets and patients across the globe requires a close looped supply system, collaborative partnerships and multi stakeholder operations and a reliable manufacturing infrastructure.
Novartis has made strong progress and today we have the broadest presence globally reinforcing our commitment to serve more patients worldwide.